Serina Therapeutics Begins First-in-Patient Dosing in Phase 1b Trial of SER‑252 for Advanced Parkinson’s Disease
- March 10, 2026
New Gene Editing Program Aims to Address Root Cause of PKU
From Psychiatric Bind to Clinical Solution: The VMAT2 Revolution in Treating Tardive Dyskinesia
Brain Cancers: FDA Approves Pembrolizumab Combo
LISTEN TO OUR PODCAST
THE LATEST FROM PATIENT WORTHY
FEATURED
UPCOMING EVENTS
SIGN UP FOR OUR NEWSLETTER
New research may offer hope for people living with #pku.
While still in development, this approach reflects growing momentum toward potentially durable, one-time genetic treatments for rare diseases.
patientworthy.com/2026/03/10/new-gene-editing-program-aims-to-address-root-cause-of-pku/
What is tardive dyskinesia? Keep reading to learn what this movement disorder is and what you need to know. Share your TD journey with us here: bit.ly/4dV7gru
#tardivedyskinesia #TDawareness #mentalhealthmatters #PatientWorthy
It was a pleasure hearing Gordon share his story during Rare Disease Week in DC! His commitment to advocacy and educating people about APDS is inspiring. Gordon was diagnosed with Activated PI3K delta syndrome (APDS).
Spreading awareness has been a passion for Gordon. He started a patient- advocacy and awareness organization called APDS RARE DISEASE COALITION
www.apdscoalition.org
"The APDS Rare Disease Coalition exists to bring hope, education, and advocacy to individuals and families affected by Activated PI3K Delta Syndrome. Founded in Monticello, Utah, our mission extends across the United States and globally. We work to raise awareness, build supportive communities, and collaborate with researchers, healthcare providers, and policymakers to improve care and quality of life."
#RareDC2026 #RareDiseaseWeek #PatientWorthy #APDS #ActivatedPI3KDeltaSyndrome #apdsadvocatesof
